Page 3 - ஆண்டு உலகளாவிய முதலீடு மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva Reports First-Half of 2021 Financial Information
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Enterome to Present at Upcoming Investor Conferences
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
INVENTIVA: Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
Revenues of €0.1m in Q1 2021
Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial
Daix (France), May 12, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of 2021, and provided an update on its collaboration with AbbVie in auto-immune diseases.